Zai Lab Reports Q2 2026 Financial Results with $105.8M Revenue and Increased Net Loss

Zai Lab Limited reported its financial results for the second quarter of 2026, revealing a net product revenue of $105.8 million, a decrease of 3% from $109.1 million in the same period last year. For the first half of 2026, total revenues reached $205.9 million, down 5% from $216.5 million in the first half of 2025. The decline in revenue was primarily attributed to reduced sales of ZEJULA and VYVGART, influenced by changes in hospital utilization patterns and pricing adjustments. However, the company noted increased sales for XACDURO and NUZYRA, driven by strong patient demand and improved market penetration.

The company’s net loss for the second quarter was $50.8 million, or $0.05 per share, compared to a loss of $40.7 million, or $0.04 per share, in the prior year. For the first half of 2026, the net loss was $101.8 million, reflecting a 14% increase from $89.2 million in the same period of 2025. The increase in losses was attributed to higher research and development expenses, which rose by 22% in the second quarter, largely due to increased licensing fees associated with collaboration agreements.

In terms of operational developments, Zai Lab launched KarXT in mainland China in June 2026, marking a significant addition to its product portfolio as the first schizophrenia therapy with a novel mechanism of action approved in over 70 years. The company is also preparing to seek inclusion of KarXT in China’s National Reimbursement Drug List (NRDL) in 2027. Additionally, Zai Lab received regulatory approvals for TIVDAK for cervical cancer treatment and continued to advance its oncology pipeline, including promising data for Zocilurtatug Pelitecan.

As of June 30, 2026, Zai Lab had cash and cash equivalents totaling $607.5 million, down from $679.6 million at the end of 2025. The company’s total assets decreased to $1.07 billion from $1.17 billion, while total liabilities increased slightly to $467.8 million. The company’s employee headcount remained stable, reflecting its ongoing commitment to maintaining operational efficiency while pursuing growth opportunities. Looking ahead, Zai Lab anticipates continued investment in research and development, with a focus on expanding its product offerings and enhancing market presence, despite the challenges posed by fluctuating revenues and ongoing losses.